metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	nivolumab plus SoC
	CheckMate 649 (PDL1 CPS>5), 2021 Lancet 2021 Jun 4;S0140-6736(21)00797-2. NCT02872116	RCT	mGC or mGEJC - L1 - HER2 neg/PDL1 positive	nivolumab plus chemotherapy	ICC (XELOX, FOLFOX)	previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma, only patients with PDL1 CPS>5	473 / 482	some concern	conclusif	demonstrated 29 % decrease in deaths (OS) (PE) demonstrated 32 % decrease in progression or deaths (PFS) (PE)
	CheckMate 649 (PDL1 CPS>1), 2021 Lancet 2021 Jun 4;S0140-6736(21)00797-2. NCT02872116	RCT	mGC or mGEJC - L1 - HER2 neg/PDL1 positive	nivolumab plus chemotherapy	ICC (XELOX, FOLFOX)	previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma, only patients with PDL1 CPS>1	641 / 655	some concern	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) suggested 26 % decrease in progression or deaths (PFS)
mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative
versus Standard of Care (SoC)
	nivolumab plus SoC
	CheckMate 649, 2021 Lancet 2021 Jun 4;S0140-6736(21)00797-2. Nature 2022 Mar;603(7903):942-948. NCT02872116	RCT	mGC or mGEJC - L1 - HER2 negative	nivolumab plus chemotherapy	ICC (XELOX, FOLFOX)	previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma	789 / 792	some concern	conclusif	demonstrated 20 % decrease in deaths (OS) (PE) suggested 23 % decrease in progression or deaths (PFS)
mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive
versus placebo plus SoC
	pembrolizumab alone
	KEYNOTE-062 (P vs C ; CPS>10), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab	placebo plus chemotherapy (cisplatin plus fluorouracil or capecitabine)	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (PDL1 CPS>10)	92 / 90	some concern	suggested	suggested 31 % decrease in deaths (OS),deaths (OS) (PE)
	pembrolizumab plus SoC
	KEYNOTE-062 (PC vs C ; CPS>1), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab plus 5FU or capcitabine plus cisplatine	placebo plus 5FU or capcitabine plus cisplatine	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma	257 / 250	low	inconclusive	inconclusive 15 % decrease in deaths (OS),deaths (OS) (PE) inconclusive 16 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE)
	KEYNOTE-062 (PC vs C ; CPS>10), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab plus chemotherapy (5FU or capecitabine, plus cisplatine)	placebo plus chemotherapy (5FU or capecitabine, plus cisplatine)	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (PDL1 CPS>10)	99 / 90	low	suggested	inconclusive 15 % decrease in deaths (OS),deaths (OS) (PE)
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-062 (P vs C ; CPS>1), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab	placebo plus chemotherapy (5FU or capecitabine plus cisplatin)	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma	256 / 250	some concern	inconclusive	statistically significant 66 % increase in progression or deaths (PFS),progression or deaths (PFS) statistically significant 71 % decrease in objective responses (ORR),objective responses (ORR)
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus irinotecan, paclitaxel
	avelumab alone
	JAVELIN Gastric 300, 2018 Ann. Oncol. 2018; 29:2052-2060 NCT02625623	RCT	mGC or mGEJC - L2 - all population	avelumab	physician's choice of chemotherapy (paclitaxel or irinotecan)	patients with unresectable, recurrent, locally advanced, or metastatic gastric cancer/gastro-oesophageal junction cancer with disease progression after second-line treatment	185 / 186	some concern	inconclusive	inconclusive 10 % increase in deaths (OS) (PE) statistically significant 73 % increase in progression or deaths (PFS) statistically significant 63 % decrease in DCR
versus paclitaxel
	pembrolizumab alone
	KEYNOTE-061 (all population), 2018 Lancet 2018; 392:123-133 NCT02370498	RCT	mGC or mGEJC - L2 - all population	pembrolizumab	paclitaxel	patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine	296 / 296	some concern	inconclusive	statistically significant 49 % increase in progression or deaths (PFS)
versus placebo
	nivolumab alone
	ATTRACTION-2 (Kang), 2017 Gastric Cancer 2019; 22:344-354 Gastric Cancer 2020; 23:143-153 Gastric Cancer 2021 Mar 20. Lancet 2017; 390:2461-2471 NCT02267343	RCT	mGC or mGEJC - L2 - all population	nivolumab	placebo	patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens	330 / 163	low	inconclusive	suggested 37 % decrease in deaths (OS) (PE) suggested 38 % decrease in deaths (OS) (extension) suggested 40 % decrease in PFS (extension) suggested 40 % decrease in progression or deaths (PFS)
versus Standard of Care (SoC)
	Ipilimumab (10 mg/kg)
	CA184-162, 2017 Clin. Cancer Res. 2017; 23:5671-5678 NCT01585987	RCT	mGC or mGEJC - L2 - all population	ipilimumab	SoC (maintenance)	patients with unresectable locally advanced/ metastatic gastric or gastroesophageal junction (GEJ) cancer who achieved at least stable disease (SD) following first-line treatment with combination platinum-fluoropyrimidine chemotherapy	57 / 57	some concern	inconclusive	statistically significant 59 % increase in progression or deaths (PFS) statistically significant 44 % increase in irPFS (PE)
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
versus paclitaxel
	pembrolizumab alone
	KEYNOTE-061 (PDL1 CPS>1), 2018 Lancet 2018; 392:123-133 Gastric Cancer 2022; 25:197-206-. NCT02370498	RCT	mGC or mGEJC - L2 - PDL1 positive	pembrolizumab	paclitaxel	patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine (PDL1 CPS>1 population)	196 / 199	some concern	inconclusive	inconclusive 18 % decrease in deaths (OS) (PE) statistically significant 27 % increase in progression or deaths (PFS) (PE)
mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative
versus Standard of Care (SoC)
	avelumab alone
	JAVELIN Gastric 100, 2020 Future Oncol 2019; 15:567-577 NCT02625610	RCT	mGC or mGEJC - M - HER2 negative	avelumab maintenance	chemotherapy	patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer. all patients received first-line chemotherapy	249 / 250	some concern	inconclusive	inconclusive 9 % decrease in deaths (OS),deaths (OS) (PE) statistically significant 38 % decrease in DCR,DCR
mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	avelumab alone
	JAVELIN Gastric 100 (PDL1>1%), 2020 Future Oncol 2019; 15:567-577 NCT02625610	RCT	mGC or mGEJC - M - HER2 neg/PDL1 positive	avelumab maintenance	chemotherapy	patients with locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer. all patients received first-line chemotherapy	30 / 24	some concern	inconclusive	inconclusive 13 % increase in deaths (OS),deaths (OS) (PE)

mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive

mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive

mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative

mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive